Market News / Story
Guardant Health, Inc. (GH) Wins EU CDx Approval for Guardant360 CDx
·
Guardant Health received CE-marking for Guardant360 CDx in Europe as a companion diagnostic to identify ER+, HER2- advanced breast cancer patients for AstraZeneca’s camizestrant, following prior approvals in the U.S. and Japan. Material Details #DetailAI Analyst View1EU CE-mark for Guardant360 CDxExpands addressable market for the test across Europe, supporting adoption and potential test volume growth.2CDx for AstraZeneca’s camizestrantLinks test usage to a new therapy…